Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2019
Prospective Multicenter Study on the Prognostic and Predictive Impact of Tumor Budding in Stage II Colon Cancer: Results From the SACURA Trial.
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00392899 (Randomized Phase III Trial of Adjuvant Chemotherapy With UFT vs. Observation in Curatively Resected Stage II Colon Cancer), which is not on this map. Cited by 85 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized Phase III Trial of Adjuvant Chemotherapy With UFT vs. Observation in Curatively Resected Stage II Colon Cancer
Who cites it
85 citing papers in PubMed.
- Prognostic value of desmoplastic reaction characterisation in stage II colon cancer: prospective validation in a Phase 3 study (SACURA Trial).British journal of cancer · 2021Trial
- Optimal Criteria for G3 (Poorly Differentiated) Stage II Colon Cancer: Prospective Validation in a Randomized Controlled Study (SACURA Trial).The American journal of surgical pathology · 2020Trial
- Emergency Surgery Independently Predicts Postoperative Recurrence in Patients with Pathologic T3N0M0 Colon Cancer: A Retrospective Single-Center Cohort Study.Current oncology (Toronto, Ont.) · 2026Article
- Impact of tumor budding on recurrence risk prediction in stage I-III colorectal cancer: a Swedish cohort study.American journal of clinical pathology · 2026Article
- Tumor Budding in Colorectal Carcinoma-From Incidental Observation to Prognostic Marker: Lessons Learned from Colorectal Cancer Assessment.Medicina (Kaunas, Lithuania) · 2026Review
- Integrating artificial intelligence (AI) into colorectal cancer reporting.The Journal of pathology · 2026Review
- Machine Learning-Based Risk Assessment of Myasthenia Gravis Onset in Thymoma Patients and Analysis of Their Correlations and Causal Relationships.Journal of imaging informatics in medicine · 2026Article
- Prognostic significance and clinicopathological association of tumor budding and poorly differentiated clusters in cutaneous malignant melanoma.Virchows Archiv : an international journal of pathology · 2026Article
- Adjuvant Tegafur-Uracil Improves Survival in Low-Risk, Mismatch Repair Proficient Stage IIA Colon Cancer: A Propensity Score-Matched Analysis.Life (Basel, Switzerland) · 2025Article
- Comprehensive single-cell transcriptome landscape of metastatic colorectal cancer identifies budding-potential cells and their interactions with cancer-associated fibroblasts.NPJ precision oncology · 2025Article
- Protocol digest of a single-arm confirmatory trial for less intensive postoperative surveillance in low-risk colorectal cancer patients: JCOG1915 (less study).Japanese journal of clinical oncology · 2025Article
- Identifying risk factors of biliary tract cancers using a large Japanese regional insurance claims database.Scientific reports · 2025Article
- Utility of comprehensive genomic profiling combined with machine learning for prognostic stratification in stage II/III colorectal cancer after adjuvant chemotherapy.International journal of clinical oncology · 2025Article
- Real-world outcomes of stage II and III colorectal cancers treated by postoperative adjuvant chemotherapy based on the mismatch repair status.Surgery today · 2025Article
- Assessment of new pathological markers in early stage colon cancer: Insights and limitations.World journal of gastrointestinal oncology · 2025Article
- Analysis of tumor budding as a prognostic factor for recurrence in patients with stage II and III colon cancer. Experience in a tertiary hospital.The oncologist · 2025Article
- Tumor aggression-defense index-a novel indicator to predicts recurrence and survival in stage II-III colorectal cancer.Journal of translational medicine · 2025Article
- Tumor budding in gastric adenocarcinoma: prognostic value and association with clinicopathological markers.Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery · 2025Article
- Implication of LAMP proteins and autophagy markers in colorectal cancer aggressiveness.Frontiers in immunology · 2025Article
- Combining immunoscore and tumor budding in colon cancer: an insightful prognostication based on the tumor-host interface.Journal of translational medicine · 2024Article
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe International Union Against Cancer highlighted tumor budding as a tumor-related prognostic factor. International assessment criteria for tumor budding were recently defined by the 2016 International Tumor Budding Consensus Conference (ITBCC2016). This study aimed to clarify the prognostic and predictive values of tumor budding in a randomized controlled trial evaluating the superiority of adjuvant chemotherapy with oral tegafur-uracil over surgery alone for stage II colon cancer (SACURA trial; ClinicalTrials.gov identifier: NCT00392899). PATIENTS AND
methodsBetween 2006 and 2010, we enrolled 991 patients from 123 institutions with stage II colon cancer. Tumor budding was diagnosed by central review on the basis of the criteria adopted in the ITBCC2016. We prospectively recorded all clinical and pathologic data, including the budding grade, and performed prognostic analyses after 5 years of completing the patients' registration.
resultsOf 991 tumors, 376, 331, and 284 were classified as BD1, BD2, and BD3, respectively; the 5-year relapse-free survival (RFS) rate was 90.9%, 85.1%, and 74.4%, respectively (
conclusionTumor budding grade on the basis of the ITBCC2016 criteria should be routinely evaluated in pathologic practice and could improve the benefit of adjuvant chemotherapy for stage II colon cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.